Acarix AB
STO:ACARIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (17.8), the stock would be worth kr-0.61 (321% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -8 | kr0.28 |
0%
|
| Industry Average | 17.8 | kr-0.61 |
-321%
|
| Country Average | 22.4 | kr-0.78 |
-379%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| SE |
A
|
Acarix AB
STO:ACARIX
|
323.8m SEK | -8 | -6.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 62.8 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 21.5 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 30.7 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 22.8 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 25.9 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 33.6 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 20.9 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 43.2 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 22.3 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 16.9 | 21 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 14.9 |
| Median | 22.4 |
| 70th Percentile | 32.4 |
| Max | 829.7 |
Other Multiples
Acarix AB
Glance View
Acarix AB is engaged in the provision of medical devices for monitoring Coronary Artery Disease. The company is headquartered in Malmo, Skane. The company went IPO on 2016-12-19. The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.
